Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Jaehyun | - |
dc.contributor.author | Song, Kee-Ho | - |
dc.contributor.author | Park, Jong Suk | - |
dc.contributor.author | Lee, Jae Hyuk | - |
dc.contributor.author | Jeong, In-Kyung | - |
dc.contributor.author | Kim, Hyun Jin | - |
dc.contributor.author | Lim, Young-Hyo | - |
dc.contributor.author | Cho, Jae-Hyoung | - |
dc.contributor.author | Choi, Sung Hee | - |
dc.contributor.author | Chung, Yoon-Sok | - |
dc.contributor.author | Kang, Eun Seok | - |
dc.date.accessioned | 2021-08-02T08:25:59Z | - |
dc.date.available | 2021-08-02T08:25:59Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/7947 | - |
dc.description.abstract | We designed a postmarketing surveillance study of linagliptin for patients with type 2 diabetes (T2D) in Korea. This prospective, observational, multicentre study investigated the safety and glycaemic effectiveness of linagliptin as monotherapy or combination therapy with other antidiabetic drugs in routine clinical practice. Endpoints were the incidence of adverse drug reactions (ADRs) and the change in HbA1c. Overall, 3119 and 2171 patients were included in the safety and effectiveness analysis sets, respectively. A total of 56 patients (1.8%) experienced ADRs. The most common ADR was gastrointestinal disorders (0.7%), followed by metabolism and nutrition disorders (0.5%). ADRs of special interest, including pancreatic diseases, cardiac diseases and hypoglycaemia, occurred in 12 patients, 11 of whom had hypoglycaemia, while one had a skin lesion. Mean HbA1c change during the study period was -0.8%. Lower body mass index, shorter diabetes duration and higher baseline HbA1c were independently associated with a better effectiveness, while the presence of diabetic complications, dyslipidaemia and the use of sulphonylureas were associated with a poor response. In conclusion, linagliptin showed an excellent safety profile and glycaemic effectiveness in Korean patients with T2D. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Blackwell Publishing Inc. | - |
dc.title | Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, Young-Hyo | - |
dc.identifier.doi | 10.1111/dom.14317 | - |
dc.identifier.scopusid | 2-s2.0-85100535372 | - |
dc.identifier.wosid | 000615704500001 | - |
dc.identifier.bibliographicCitation | Diabetes, Obesity and Metabolism, v.23, no.5, pp.1208 - 1212 | - |
dc.relation.isPartOf | Diabetes, Obesity and Metabolism | - |
dc.citation.title | Diabetes, Obesity and Metabolism | - |
dc.citation.volume | 23 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1208 | - |
dc.citation.endPage | 1212 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | alanine aminotransferase | - |
dc.subject.keywordPlus | antidiabetic agent | - |
dc.subject.keywordPlus | hemoglobin A1c | - |
dc.subject.keywordPlus | linagliptin | - |
dc.subject.keywordPlus | metformin | - |
dc.subject.keywordPlus | sulfonylurea derivative | - |
dc.subject.keywordPlus | vildagliptin | - |
dc.subject.keywordPlus | antidiabetic agent | - |
dc.subject.keywordPlus | dipeptidyl peptidase IV inhibitor | - |
dc.subject.keywordPlus | glycosylated hemoglobin | - |
dc.subject.keywordPlus | linagliptin | - |
dc.subject.keywordPlus | abdominal pain | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | alanine aminotransferase blood level | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | benign neoplasm | - |
dc.subject.keywordPlus | body mass | - |
dc.subject.keywordPlus | clinical practice | - |
dc.subject.keywordPlus | connective tissue disease | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | diabetic complication | - |
dc.subject.keywordPlus | diabetic patient | - |
dc.subject.keywordPlus | disease duration | - |
dc.subject.keywordPlus | dizziness | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | dyslipidemia | - |
dc.subject.keywordPlus | dyspepsia | - |
dc.subject.keywordPlus | ear disease | - |
dc.subject.keywordPlus | eye disease | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | gastrointestinal disease | - |
dc.subject.keywordPlus | heart disease | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hypoglycemia | - |
dc.subject.keywordPlus | incidence | - |
dc.subject.keywordPlus | infection | - |
dc.subject.keywordPlus | infestation | - |
dc.subject.keywordPlus | inner ear disease | - |
dc.subject.keywordPlus | kidney disease | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | malignant neoplasm | - |
dc.subject.keywordPlus | mental disease | - |
dc.subject.keywordPlus | metabolic disorder | - |
dc.subject.keywordPlus | monotherapy | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | musculoskeletal disease | - |
dc.subject.keywordPlus | nausea | - |
dc.subject.keywordPlus | neurologic disease | - |
dc.subject.keywordPlus | non insulin dependent diabetes mellitus | - |
dc.subject.keywordPlus | nutritional disorder | - |
dc.subject.keywordPlus | observational study | - |
dc.subject.keywordPlus | open study | - |
dc.subject.keywordPlus | pancreas disease | - |
dc.subject.keywordPlus | postmarketing surveillance | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordAuthor | antidiabetic drug | - |
dc.subject.keywordAuthor | linagliptin | - |
dc.identifier.url | https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14317 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.